SBI-5844

SBI-5844 (0-10 µM; 24 h) potently reduces the levels of HCoV-OC43 spike protein and nucleocapsid protein in infected Vero E6 cells^[1].
SBI-5844 (0.08-10 µM; 48 h) dose-dependently and potently reduces the infection rate of HCoV-OC43 in Vero E6 cells^[1].
SBI-5844 (0.625-10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels in infected Vero E6 cells in a dose-dependent manner, with nearly complete inhibition at 10 µM^[1].
SBI-5844 (5-20 µM) disrupts the eIF4F complex in HCoV-OC43-infected A549 cells by reducing the binding level of eIF4G1-eIF4E and increasing the binding level of 4EBP1-eIF4E^[1].
SBI-5844 (10 µM; 24 h) reduces the interaction between eIF4E and eIF4G in live A549 cells^[1].
SBI-5844 (10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels and reverses infection-induced changes in host gene expression, aligning the state of both Vero E6 and A549 cells with that of uninfected cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.